Drug Profile


Alternative Names: Anti-TRAIL R2 monoclonal antibody; HGS-TR2J; KMTR-2; TRAIL-R2 mAb

Latest Information Update: 21 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Genome Sciences; Kirin Brewery
  • Developer Human Genome Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 16 Apr 2008 Discontinued - Phase-I for Solid tumours in Canada (unspecified route)
  • 05 Nov 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 18 Oct 2004 Phase-I clinical trials in Solid tumours in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top